

Superficial Spreading Basal Cell Carcinoma of the Nose

Y. Smulders MD¹, G. Bertasi MD, PhD²

¹Velthuis Clinics, the Netherlands, ²University of Padua, Italy

Basal cell carcinomas (BCC) are abnormal, uncontrolled growths or lesions that arise in the skin's basal cells, which line the deepest layer of the epidermis (the outermost layer of the skin). BCCs often look like open sores, red patches, pink growths, shiny bumps, or scars and are usually caused by a combination of cumulative and intense sun exposure. Patients presenting with BCCs often report a slowly enlarging lesion that does not heal and bleeds when traumatized. As tumors most commonly occur on the face, patients frequently provide a history of an acne bump that occasionally bleeds.

People who experience sunburns are more likely to develop skin cancer than those who do not; however, sunlight can damage the skin regardless of the presence of a sunburn. Patients with BCCs often have a history of chronic sun exposure, including recreational sun exposure (e.g., sunbathing, outdoor sports, fishing, boating) and occupational sun exposure (e.g., farming, construction).

History of any prior treatment to the index tumor should be elicited, as well as history of any prior non-melanoma skin cancer. In patients with recurrent tumors, deeper invasion should be expected. Recurrence following radiation therapy is often more aggressive.

The following case presentation involves excision of BCC at the nose and grafting with LifeNet Health Acellular Dermal Matrix (ADM).

PATIENT

- 39 years old, Male, in otherwise good health

DIAGNOSIS

- BCC on right ala nasi (cartilaginous flap on the lateral surface of nose)

TREATMENT

- Surgical excision
- Non meshed acellular dermal matrix (LifeNet Health ADM, LifeNet Health, Virginia, USA) was placed and fixed with interrupted sutures

CONCLUSION

- Uneventful post-operative course with no swelling or major exudate
- The acellular demal matrix completely closed the wound within 15 weeks and enabled a successful cosmetic outcome
- LifeNet Health ADM provided a safe and effective treatment option for this surgical reconstruction procedure



Figure 1. Pre operative basal cell carcinoma on right ala nasi



Figure 2. Four days post operative with LifeNet Health ADM visible



Figure 3. Two weeks post operative



Figure 4. Fifteen weeks post operative and the wound is completely closed

1. Raasch BA, Buettner PG, Garbe C. Basal cell carcinoma: histological classification and body-site distribution. *Br J Dermatol.* 2006;155:401–7. [[PubMed](#)]
2. Buljan M, Bulat V, Situm M, Mihic LL, Stanic-Duktaj S. Variations in clinical presentation of basal cell carcinoma. *ActaClin Croat.* 2008;47:25–30. [[PubMed](#)]
3. Chen CC, Chen CL. Clinical and histopathologic findings of superficial basal cell carcinoma: a comparison with other basal cell carcinoma subtypes. *J Chin Med Assoc.* 2006;69:364–71. [[PubMed](#)]
4. Lovatt TJ, Lear JT, Bastrilles J, et al. Associations between ultraviolet radiation, basal cell carcinoma site and histology, host characteristics, and rate of development of further tumors. *J Am Acad Dermatol.* 2005;52:468–73. [[PubMed](#)]
5. Kennedy C, Bajdik CD, Willemze R, De Grujil FR, Bouwes Bavinck JN. The influence of painful sunburns and lifetime sun exposure on the risk of actinic keratoses, seborrheic warts, melanocytic nevi, atypical nevi, and skin cancer. *J Invest Dermatol.* 2003;120:1087–93. [[PubMed](#)]
6. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs surgery in Australia, part I: experience over 10 years. *J Am Acad Dermatol.* 2005;53:445–51. [[PubMed](#)]
7. Skelton LA. The effective treatment of basal cell carcinoma. *Br J Nurs.* 2009;18(346):8–50. [[PubMed](#)]
8. Muller FM, Dawe RS, Moseley H, Fleming CJ. Randomized comparison of Mohs micrographic surgery and surgical excision for small nodular basal cell carcinoma: tissue-sparing outcome. *Dermatol Surg.* 2009;35:1349–54. [[PubMed](#)]
9. Saldanha G, Fletcher A, Slater DN. Basal cell carcinoma: a dermatopathological and molecular biological update. *Br J Dermatol.* 2003;148:195–202. [[PubMed](#)]
10. Scalvenzi M, Lembo S, Francia MG, Balato A. Dermoscopic patterns of superficial basal cell carcinoma. *Int J Dermatol.* 2008;47:1015–18. [[PubMed](#)]
11. Smeets NW, Kuijpers DI, Nelemans P, et al. Mohs' micrographic surgery for treatment of basal cell carcinoma of the face—results of a retrospective study and review of the literature. *Br J Dermatol.* 2004;151:141–7. [[PubMed](#)]
12. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. *Cochrane Database Syst Rev.* 2007;4:CD003412. [[PubMed](#)]
13. Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I. Pharmacological treatments for basal cell carcinoma. *Drugs.* 2007;67:915–34. [[PubMed](#)]
14. Ezughah FI, Affleck AG, Evans A, Ibbotson SH, Fleming CJ. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream. *J Dermatol Treat.* 2008;19:156–8. [[PubMed](#)]